S&P 500   3,922.73 (-1.90%)
DOW   33,452.93 (-1.46%)
QQQ   281.13 (-2.26%)
AAPL   142.51 (-2.81%)
MSFT   244.40 (-2.32%)
META   114.41 (-6.55%)
GOOGL   96.80 (-2.69%)
AMZN   88.45 (-2.81%)
TSLA   179.23 (-1.76%)
NVDA   159.20 (-4.15%)
NIO   13.24 (+3.44%)
BABA   91.13 (+0.67%)
AMD   69.89 (-5.07%)
T   19.11 (+1.92%)
MU   53.47 (-1.05%)
CGC   3.65 (-15.51%)
F   13.19 (-1.42%)
GE   84.70 (+0.05%)
DIS   92.39 (-3.69%)
AMC   6.79 (-8.86%)
PYPL   72.02 (-2.17%)
PFE   49.60 (-2.23%)
NFLX   305.15 (-2.38%)
S&P 500   3,922.73 (-1.90%)
DOW   33,452.93 (-1.46%)
QQQ   281.13 (-2.26%)
AAPL   142.51 (-2.81%)
MSFT   244.40 (-2.32%)
META   114.41 (-6.55%)
GOOGL   96.80 (-2.69%)
AMZN   88.45 (-2.81%)
TSLA   179.23 (-1.76%)
NVDA   159.20 (-4.15%)
NIO   13.24 (+3.44%)
BABA   91.13 (+0.67%)
AMD   69.89 (-5.07%)
T   19.11 (+1.92%)
MU   53.47 (-1.05%)
CGC   3.65 (-15.51%)
F   13.19 (-1.42%)
GE   84.70 (+0.05%)
DIS   92.39 (-3.69%)
AMC   6.79 (-8.86%)
PYPL   72.02 (-2.17%)
PFE   49.60 (-2.23%)
NFLX   305.15 (-2.38%)
S&P 500   3,922.73 (-1.90%)
DOW   33,452.93 (-1.46%)
QQQ   281.13 (-2.26%)
AAPL   142.51 (-2.81%)
MSFT   244.40 (-2.32%)
META   114.41 (-6.55%)
GOOGL   96.80 (-2.69%)
AMZN   88.45 (-2.81%)
TSLA   179.23 (-1.76%)
NVDA   159.20 (-4.15%)
NIO   13.24 (+3.44%)
BABA   91.13 (+0.67%)
AMD   69.89 (-5.07%)
T   19.11 (+1.92%)
MU   53.47 (-1.05%)
CGC   3.65 (-15.51%)
F   13.19 (-1.42%)
GE   84.70 (+0.05%)
DIS   92.39 (-3.69%)
AMC   6.79 (-8.86%)
PYPL   72.02 (-2.17%)
PFE   49.60 (-2.23%)
NFLX   305.15 (-2.38%)
S&P 500   3,922.73 (-1.90%)
DOW   33,452.93 (-1.46%)
QQQ   281.13 (-2.26%)
AAPL   142.51 (-2.81%)
MSFT   244.40 (-2.32%)
META   114.41 (-6.55%)
GOOGL   96.80 (-2.69%)
AMZN   88.45 (-2.81%)
TSLA   179.23 (-1.76%)
NVDA   159.20 (-4.15%)
NIO   13.24 (+3.44%)
BABA   91.13 (+0.67%)
AMD   69.89 (-5.07%)
T   19.11 (+1.92%)
MU   53.47 (-1.05%)
CGC   3.65 (-15.51%)
F   13.19 (-1.42%)
GE   84.70 (+0.05%)
DIS   92.39 (-3.69%)
AMC   6.79 (-8.86%)
PYPL   72.02 (-2.17%)
PFE   49.60 (-2.23%)
NFLX   305.15 (-2.38%)
NASDAQ:AMGN

Amgen - AMGN Stock Forecast, Price & News

$282.45
-2.46 (-0.86%)
(As of 12/6/2022 03:16 PM ET)
Add
Compare
Today's Range
$281.73
$287.35
50-Day Range
$225.40
$292.39
52-Week Range
$205.97
$296.67
Volume
91,709 shs
Average Volume
2.96 million shs
Market Capitalization
$150.71 billion
P/E Ratio
22.65
Dividend Yield
2.72%
Price Target
$248.19

Amgen MarketRank™ Forecast

Analyst Rating
Hold
2.07 Rating Score
Upside/​Downside
12.0% Downside
$249.47 Price Target
Short Interest
Healthy
1.96% of Float Sold Short
Dividend Strength
Strong
Based on Four Factors
Sustainability
-2.42
Upright™ Environmental Score
News Sentiment
0.36mentions of Amgen in the last 14 days
Based on 15 Articles This Week
Insider Trading
Selling Shares
$159,979 Sold Last Quarter
Proj. Earnings Growth
5.62%
From $17.63 to $18.62 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.72 out of 5 stars

Medical Sector

83rd out of 1,023 stocks

Biological Products, Except Diagnostic Industry

11th out of 170 stocks

AMGN stock logo

About Amgen (NASDAQ:AMGN) Stock

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.

Receive AMGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Amgen and its competitors with MarketBeat's FREE daily newsletter.

AMGN Stock News Headlines

Is Mid-Cap Neurocrine Biosciences A Buy After Blowout Q3 Report? (AMGN)
Neurocrine Biosciences trended higher with the broad market Thursday, coming within a penny of Tuesday’s high of $125.99. It is forming a bullish channel.
Without Graphite, There Would Be ZERO EV Batteries!
Investors constantly hear that lithium is the key to powering the transition to green energy. Truth is, today's EV batteries contain more graphite in volume than any other essential ingredients.
Is Amgen Stock a Buy for Income Investors?
Elon Musk and Bill Gates Agree On Nuclear Energy?
From Elon Musk to Bill Gates to politicians on both sides of the aisle, powerful people are now backing the expanded use of nuclear energy. They believe that safe, advanced nuclear technologies will play a vital role in our clean energy transition. Unfortunately, we're far too dependent on Russia for our uranium supply. That's why we desperately need more DOMESTIC sources of the yellow metal that fuels nuclear reactors.
Why Horizon Therapeutics Stock Is Skyrocketing Today
AMGEN TO WEBCAST INVESTOR CALL AT WCIRDC 2022
Brokerages Set Amgen Inc. (NASDAQ:AMGN) Target Price at $248.19
Is This Biotech Stock a Buy for Under $3?
Top Research Reports for Novo Nordisk, Amgen & ADP
How Is The Market Feeling About Amgen?
Dow Movers: CRM, AMGN
See More Headlines
Receive AMGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Amgen and its competitors with MarketBeat's FREE daily newsletter.

AMGN Company Calendar

Ex-Dividend for 9/8 Dividend
8/17/2022
Dividend Payable
9/08/2022
Last Earnings
11/03/2022
Ex-Dividend for 12/8 Dividend
11/16/2022
Today
12/06/2022
Dividend Payable
12/08/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
2/06/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:AMGN
CUSIP
03116210
Employees
24,200
Year Founded
1980

Price Target and Rating

Average Stock Price Forecast
$249.47
High Stock Price Forecast
$310.00
Low Stock Price Forecast
$182.00
Forecasted Upside/Downside
-12.1%
Consensus Rating
Hold
Rating Score (0-4)
2.07
Research Coverage
13 Analysts

Profitability

Net Income
$5.89 billion
Pretax Margin
29.35%

Debt

Sales & Book Value

Annual Sales
$25.98 billion
Cash Flow
$23.38 per share
Book Value
$12.00 per share

Miscellaneous

Free Float
531,125,000
Market Cap
$150.71 billion
Optionable
Optionable
Beta
0.65

Social Links


Key Executives

  • Mr. Robert A. BradwayMr. Robert A. Bradway (Age 59)
    Chairman, CEO & Pres
    Comp: $5.81M
  • Mr. Peter H. GriffithMr. Peter H. Griffith (Age 63)
    Exec. VP & CFO
    Comp: $2.66M
  • Mr. Esteban Santos (Age 54)
    Exec. VP of Operations
    Comp: $2.61M
  • Dr. David M. Reese M.D. (Age 59)
    Exec. VP of R&D
    Comp: $2.79M
  • Mr. Murdo Gordon (Age 55)
    Exec. VP of Global Commercial Operations
    Comp: $2.82M
  • Ms. Linda H. Louie
    VP of Fin. & Chief Accounting Officer
  • Mr. Mike Zahigian
    Sr. VP & Chief Information Officer
  • Mr. Arvind Sood
    VP of Investor Relations
  • Mr. Jonathan P. GrahamMr. Jonathan P. Graham (Age 61)
    Exec. VP, Gen. Counsel & Sec.
  • Ms. Nancy A. GrygielMs. Nancy A. Grygiel (Age 54)
    Sr. VP of Worldwide Compliance & Bus. Ethics and Chief Compliance Officer













AMGN Stock - Frequently Asked Questions

Should I buy or sell Amgen stock right now?

13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amgen in the last year. There are currently 4 sell ratings, 5 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" AMGN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in AMGN, but not buy additional shares or sell existing shares.
View AMGN analyst ratings
or view top-rated stocks.

What is Amgen's stock price forecast for 2023?

13 equities research analysts have issued 1 year price objectives for Amgen's stock. Their AMGN share price forecasts range from $182.00 to $310.00. On average, they expect the company's share price to reach $249.47 in the next year. This suggests that the stock has a possible downside of 11.7%.
View analysts price targets for AMGN
or view top-rated stocks among Wall Street analysts.

How have AMGN shares performed in 2022?

Amgen's stock was trading at $224.97 at the beginning of the year. Since then, AMGN stock has increased by 25.6% and is now trading at $282.45.
View the best growth stocks for 2022 here
.

Are investors shorting Amgen?

Amgen saw a decrease in short interest during the month of November. As of November 15th, there was short interest totaling 10,430,000 shares, a decrease of 11.4% from the October 31st total of 11,770,000 shares. Based on an average daily volume of 2,800,000 shares, the short-interest ratio is presently 3.7 days. Approximately 2.0% of the shares of the stock are short sold.
View Amgen's Short Interest
.

When is Amgen's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, February 6th 2023.
View our AMGN earnings forecast
.

How were Amgen's earnings last quarter?

Amgen Inc. (NASDAQ:AMGN) issued its quarterly earnings data on Thursday, November, 3rd. The medical research company reported $4.70 EPS for the quarter, beating the consensus estimate of $4.43 by $0.27. The medical research company earned $6.65 billion during the quarter, compared to the consensus estimate of $6.56 billion. Amgen had a trailing twelve-month return on equity of 287.23% and a net margin of 25.96%. The business's revenue was down .8% compared to the same quarter last year. During the same period in the previous year, the firm earned $4.67 EPS.
Read the conference call transcript
.

How often does Amgen pay dividends? What is the dividend yield for Amgen?

Amgen announced a quarterly dividend on Friday, October 28th. Investors of record on Thursday, November 17th will be paid a dividend of $1.94 per share on Thursday, December 8th. This represents a $7.76 annualized dividend and a yield of 2.75%. The ex-dividend date is Wednesday, November 16th.
Read our dividend analysis for AMGN
.

Is Amgen a good dividend stock?

Amgen (NASDAQ:AMGN) pays an annual dividend of $7.76 per share and currently has a dividend yield of 2.72%. The company has been increasing its dividend for 10 consecutive years, indicating the company has a strong committment to maintain and grow its dividend. The dividend payout ratio is 62.23%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, AMGN will have a dividend payout ratio of 41.68% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for AMGN.

What guidance has Amgen issued on next quarter's earnings?

Amgen issued an update on its FY 2022 earnings guidance on Thursday, November, 10th. The company provided EPS guidance of $17.25-$17.85 for the period, compared to the consensus earnings per share estimate of $17.50. The company issued revenue guidance of $26.00 billion-$26.30 billion, compared to the consensus revenue estimate of $26.14 billion.

What is Robert A. Bradway's approval rating as Amgen's CEO?

1,239 employees have rated Amgen Chief Executive Officer Robert A. Bradway on Glassdoor.com. Robert A. Bradway has an approval rating of 91% among the company's employees. This puts Robert A. Bradway in the top 30% of approval ratings compared to other CEOs of publicly-traded companies. 81.0% of employees surveyed would recommend working at Amgen to a friend.

What other stocks do shareholders of Amgen own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Amgen investors own include Johnson & Johnson (JNJ), NVIDIA (NVDA), Intel (INTC), Cisco Systems (CSCO), Pfizer (PFE), AbbVie (ABBV), Walt Disney (DIS), AT&T (T), Alibaba Group (BABA) and Home Depot (HD).

What is Amgen's stock symbol?

Amgen trades on the NASDAQ under the ticker symbol "AMGN."

Who are Amgen's major shareholders?

Amgen's stock is owned by many different retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (8.89%), BlackRock Inc. (8.78%), State Street Corp (5.45%), Primecap Management Co. CA (2.92%), Royal Bank of Canada (1.14%) and Bank of New York Mellon Corp (1.12%). Insiders that own company stock include David Piacquad, Jonathan P Graham, Jonathan P Graham, Nancy A Grygiel, Nancy A Grygiel, R Sanders Williams, Robert Eckert, Ronald D Sugar and Ronald D Sugar.
View institutional ownership trends
.

How do I buy shares of Amgen?

Shares of AMGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Amgen's stock price today?

One share of AMGN stock can currently be purchased for approximately $282.45.

How much money does Amgen make?

Amgen (NASDAQ:AMGN) has a market capitalization of $150.71 billion and generates $25.98 billion in revenue each year. The medical research company earns $5.89 billion in net income (profit) each year or $12.47 on an earnings per share basis.

How many employees does Amgen have?

The company employs 24,200 workers across the globe.

Does Amgen have any subsidiaries?
The following companies are subsidiares of Amgen: Abgenix, Alantos Pharmaceuticals, Amgen Canada Inc., Amgen Europe GmbH, Amgen Fremont Inc., Amgen Global Finance B.V., Amgen GmbH Germany, Amgen Ilaç Ticaret Limited Şirketi, Amgen K-A Inc., Amgen Manufacturing Limited, Amgen Research Munich GmbH, Amgen Rockville Inc., Amgen S.A., Amgen S.A.S., Amgen S.p.A., Amgen SF LLC, Amgen Singapore Manufacturing Pte. Ltd., Amgen Technology Ireland Unlimited Company, Amgen Technology Limited, Amgen USA Inc., Amgen Worldwide Holdings B.V., Avidia, Bergamo, BioVex, BioVex Inc., Catherex, Catherex, DeCODE Genetics, Dezima Pharma, Filgrastim and Pegfilgrastim, Five Prime Therapeutics, Five Prime Therapeutics Inc., Gensenta İlaç Sanayi ve Ticaret Anonim Şirketi, Ilypsa, Immunex, Immunex Corporation, Immunex Rhode Island Corporation, KAI Pharmaceuticals, KAI Pharmaceuticals Inc., Kinetix Pharmaceuticals, Laboratorio Quimico Farmaceutico Bergamo, MN Pharmaceuticals, Micromet, Nuevolution, Onyx Pharmaceuticals, Onyx Pharmaceuticals Inc., Onyx Therapeutics Inc., Otezla, Rodeo Therapeutics, Saga Investments Coöperatief U.A., Synergen, TeneoBio, TeneoBio Inc., Tularik, deCODE Genetics ehf, and llypsa Inc..
Read More
How can I contact Amgen?

Amgen's mailing address is ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA, 91320. The official website for the company is www.amgen.com. The medical research company can be reached via phone at (805) 447-1000, via email at investor.relations@amgen.com, or via fax at 805-447-1010.

This page (NASDAQ:AMGN) was last updated on 12/6/2022 by MarketBeat.com Staff